EUCTR2020-003960-22-AT进行中（未招募）1 期
Prospective Window of opportunity trial of 3 weeks neoadjuvant Anastrozole in Postmenopausal Women with Estrogen receptor positive (ER+) Breast Cancer
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Ability of subject to understand character and individual consequences of clinical trial
- •postmenopausal women, postmenopausal status is defined either by: • Prior bilateral oophorectomy or • amenorrhea for 12 or more months
- •only women that receive an aromatase inhibitor as their standard treatment after surgery will be eligible for the Trial
- •ER+, breast cancer, first diagnosed
- •breast cancers with a tumor size >/= cT1c.
- •Not legally incapacitated
- •Written informed consent (must be available before enrolment in the trial)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •prior breast cancer specific therapy
- •inflammatory cancers
- •Any medical condition (e.g. substance abuse) that may, in the clinical judgement of the investigator, independently influence the subject’s outcome during this study
- •known hypersensitivity to anastrozole or to any of the excipients
- •Participation in other clinical trials using investigational drug planned, during the active treatment phase
- •Not being able to comprehend the German language
- •Previously included in this trial (no patient may be included more than once)
- •Current infection of any kind, at the time of treatment start
- •Inflammation including autoimmune disease and active allergy
- •Breast feeding
- •Pregnancy
- •Osteoporosis
- •Severe hepatic or renal impairment
研究者
相似试验
进行中（未招募）
1 期
Prospektive Studie für neoadjuvantes Anastrozol bei postmenopausalen Frauen mit Östrogenrezepetor-positivem BrustkrebsEUCTR2018-000112-21-DERuprecht-Karls-Universität Heidelberg, Medizinische Fakultät, vertreten durch das Universitätsklinikum Heidelberg100
进行中（未招募）
1 期
Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged =9 to <15 YearsDengue feverMedDRA version: 20.1Level: LLTClassification code 10012312Term: Dengue fever virus infectionSystem Organ Class: 100000004862EUCTR2022-003339-24-Outside-EU/EEATakeda Vaccines, Inc.
进行中（未招募）
1 期
A phase III, open, non-randomized, trial to evaluate the immunogenicity and safety of a two-dose schedule of the A/California/7/2009 (H1N1)v-like candidate vaccine manufactured in Dresden adjuvanted with AS03A, in adults aged 18 years and above. - FLU D-PAN H1N1-022EUCTR2009-015008-25-FRGlaxoSmithKline Biologicals300
进行中（未招募）
1 期
A RANDOMISED, OPEN-LABEL PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF BEXAROTENE (TARGRETIN) CAPSULES COMBINED WITH PUVA, COMPARED TO PUVA TREATMENT ALONE IN PATIENTS WITH MYCOSIS FUNGOIDES.CUTANEOUS T CELL LYMPHOMA.EUCTR2004-003701-24-ITE.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER
进行中（未招募）
不适用
RANDOMIZED PHASE III TRIAL OF PREOPERATIVE VERSUS POSTOPERATIVE CHEMOTHERAPY WITH CISPLATIN AND GEMCITABINE IN STAGE IB-IIIA NON-SMALL CELL LUNG CANCER NSCLC - POP 01eoadjuvant treatmento for early stage non small cell lung cancerMedDRA version: 9.1Level: LLTClassification code 10061873Term: Non-small cell lung cancerEUCTR2006-002708-33-ITISTITUTI FISIOTERAPICI OSPITALIERI